The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure

This study reports preclinical data showing that the interleukin (IL)-1β modulation is a new promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial infarction, administration...

Descrición completa

Detalles Bibliográficos

Principais autores:	Najah Harouki, BS, Lionel Nicol, PhD, Isabelle Remy-Jouet, PhD, Jean-Paul Henry, BS, Anais Dumesnil, BS, Annie Lejeune, BS, Sylvanie Renet, BS, Francesca Golding, BS, Zoubir Djerada, PhD, Didier Wecker, PhD, Virginie Bolduc, PhD, Muriel Bouly, PhD, Jerome Roussel, PhD, Vincent Richard, PhD, Paul Mulder, PhD
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2017-08-01
Series:	JACC: Basic to Translational Science
Assuntos:	cardiovascular function heart failure IL-1β ischemia/reperfusion
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2452302X17301511
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!